MedTrace Logo

Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists (RADOA). Focus on New Antidots

NCT03537521 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2020-07-17

No results posted yet for this study

Summary

Patients treated with Vitamin K antagonists (VKA) or direct oral anticoagulants as Rivaroxaban, Apixaban, Edoxaban or Dabigatran, who experience severe bleeding and/or need urgent interventions/operations that cannot wait are included in this registry, or during emergency operations

Conditions

  • Severe Bleeding
  • Urgent Surgery

Interventions

PROCEDURE

Urgent surgery which can not be postponed to the next 24 hrs

The urgent surgical intervention is not part of the registry protocol. The intervention is the acute event that leads to enrollment in the registry. It might be e.g. the surgical treatment of a trauma, fall, acute abdomen, appendicitis or anything else.

Sponsors & Collaborators

  • Cardioangiologisches Centrum Bethanien

    lead OTHER

Principal Investigators

  • Edelgard Lindhoff-Last, Prof. · CCB Studienzentrum GmbH

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-30
Primary Completion
2022-04-30
Completion
2023-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03537521 on ClinicalTrials.gov